Skip to content
News

Ten63 Therapeutics Announces Multi-Target Drug Discovery Collaboration with Boehringer Ingelheim

Ten63 is a Duke University start-up and DCP portfolio company out of the lab of Professor Bruce Donald (Computer Science, Trinity).